Topic

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Articles

After years of discussions around pricing, UK governmental bodies and Vertex have finally reached an agreement on cystic fibrosis treatments.


Striking a Landmark Deal

Rita Peters is the former editorial director of 

Pharmaceutical Technology, Pharmaceutical Technology Europe

Climbing out of a reputation hole starts with adopting a quality culture.

Image Repair Must Get to the Root Cause

With no plausibly approvable deal on the table in the UK government at the moment, it is possible that Brexit could be extended even further.


The Never-Ending Brexit?

Susan J. Schniepp is a fellow at Regulatory Compliance Associates, Inc. and a member of Pharmaceutical Technology's Editorial Advisory Board.

Data supporting the quality and safety of product must meet the ALCOA+ elements in order to avoid regulatory citations for data integrity issues, says Susan J. Schniepp, executive vice-president of post-approval pharma and distinguished fellow, Regulatory Compliance Associates.

ALCOA+ and Data Integrity

Government statistics show that pharma can be an illustrious career for graduates, which must be taken advantage of by industry to avoid skills shortages.


Pharma’s Got Talent?

As a potential ‘no-deal’ Brexit looms, pharma companies and industry bodies are preparing for the worst-case scenario but hoping that the UK won’t end up with a disorderly exit from the EU.

The Big Deal Behind the ‘No-Deal’ Scenario

Pharmaceutical Technology Europe celebrates 30 years in publishing the latest insights, analysis, and developments of the bio/pharma industry.

Celebrating in Style

Much has changed in the bio/pharma industry over three decades. In this special feature, the editors take a trip down memory lane, highlighting some of the major happenings of the past 30 years.


Standing the Test of Time

Stephen Maddocks is senior pharmacopoeial scientist at the British Pharmacopoeia.

Peter Crowley is principal pharmacopoeial scientist at the British Pharmacopoeia.

MHRA has launched a consultation to gain a greater understanding of the potential application of AQbD in pharmacopoeial standards and the future of medicines standards.

AQbD, the Evolution of Pharmacopoeial Standards?

As drug supply chain security is of paramount importance, could radio-frequency identification solutions provide the optimal solution for pharma companies?

Viewpoints